How do I subscribe to ongoing alerts?

Subscribe to /feed/company/istituto-romagnolo-per-lo-studio-dei-tumori-dino-amadori-irst-s-r-l-irccs.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS pipeline: 0 marketed, 0 filed, 6 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 7 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Arm A: FOLFIRI or FOLFOX + Bevacizumab	Arm A: FOLFIRI or FOLFOX + Bevacizumab	phase 3	Chemotherapy combination + VEGF inhibitor	DNA (chemotherapy); VEGF (bevacizumab)	Oncology
Low intensity therapies	Low intensity therapies	phase 3			Oncology
Arm D: FOLFIRI or FOLFOX plus CETUXIMAB	Arm D: FOLFIRI or FOLFOX plus CETUXIMAB	phase 3	Chemotherapy combination with monoclonal antibody	EGFR (epidermal growth factor receptor)	Oncology
IL2	IL2	phase 3	Cytokine immunotherapy	IL-2 receptor	Oncology
Arm B: FOLFIRI or FOLFOX	Arm B: FOLFIRI or FOLFOX	phase 3	Combination chemotherapy regimen	DNA (topoisomerase I for irinotecan; DNA cross-linking for oxaliplatin; thymidylate synthase for 5-FU)	Oncology
High intensity therapies	High intensity therapies	phase 3			Oncology

Therapeutic area mix

Oncology · 9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

European Organisation for Research and Treatment of Cancer - EORTC · 2 shared drug classes
Agenus Inc. · 1 shared drug class
AstraZeneca · 1 shared drug class
Amgen · 1 shared drug class
Asan Medical Center · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Alliance for Clinical Trials in Oncology · 1 shared drug class
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS:

Cite this brief

Drug Landscape (2026). Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/istituto-romagnolo-per-lo-studio-dei-tumori-dino-amadori-irst-s-r-l-irccs. Accessed 2026-05-17.